RxDoctor Payments Data

Melissa Kellis

Gerontology · Springfield, OHNPI 1376058701

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 35.8% of the total.

$2,464in general payments, 2019–2025

Across 65 payments — averaging $37.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$882
  • E.r. Squibb & Sons, L.L.C.$697
  • Boston Scientific$324
  • Novartis$135
  • Amgen$127
  • Philips North America LLC$50
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$2,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,464 in reported general payments places this provider in the 85th percentile of 361 gerontology providers in Ohio.

See all gerontology providers in Ohio

Medicare billing

Part B allowed, 2024
$77,724
Medicare patients
543
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$327,375
XareltoRivaroxaban86$100,106
Repatha SureclickEvolocumab74$72,617
JardianceEmpagliflozin80$63,678
EntrestoSacubitril/Valsartan37$45,149
MultaqDronedarone Hcl20$21,194
BrilintaTicagrelor26$15,178
Praluent PenAlirocumab15$14,828
Repatha SyringeEvolocumab15$14,339
Ranolazine ErRanolazine55$7,122
Diltiazem 24hr Er (Cd)Diltiazem Hcl179$5,310
Metoprolol Succinate326$4,514
ClopidogrelClopidogrel Bisulfate322$3,530
Atorvastatin Calcium309$3,460
Midodrine Hcl51$3,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$327,375349 claims
Johnson & JohnsonXarelto$882$100,10686 claims
Boehringer IngelheimJardiance$19$63,67880 claims
NovartisEntresto$135$45,14937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 361 gerontology providers in Ohio.

Other gerontology in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →